XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.3
Note 6 - Marketable Equity Securities
 9 Months Ended
Sep. 30, 2024
Notes to Financial Statements  
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

6.

Marketable Equity Securities

 

In April 2023, the Company received shares of common stock of Harvard Apparatus Regenerative Technology, Inc. (“HRGN”, formerly known as Biostage, Inc.) in connection with settlement of indemnification obligations related to litigation which was resolved during the year ended December 31, 2022. As of December 31, 2023, these shares had an estimated fair value $3.5 million and are included in the consolidated balance sheet as a component of other long-term assets. During the nine months ended September 30, 2024, the Company sold its HRGN shares for $1.9 million and recorded a loss on equity securities of $1.6 million. The Company recorded unrealized gains (losses) of $1.2 million and $(0.4) million during the three and nine months ended September 30, 2023, respectively.